Document Type

Article

Publication Date

5-1-2016

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Expert Review of Clinical Pharmacology

Volume 8, Issue 3, May 2015, Pages 321-334.

The published version is available at DOI: 10.1586/17512433.2015.1034689. Copyright © Informa

Abstract

Posaconazole, a broad-spectrum triazole antifungal agent, is approved for the prevention of invasive aspergillosis and candidiasis in addition to the treatment of oropharyngeal candidiasis. There is evidence of efficacy in the treatment and prevention of rarer, more difficult-to-treat fungal infections. Posaconazole oral suspension solution has shown limitations with respect to fasting state absorption, elevated gastrointestinal pH and increased motility. The newly approved delayed-release oral tablet and intravenous solution formulations provide an attractive treatment option by reducing interpatient variability and providing flexibility in critically ill patients. On the basis of clinical experience and further clinical studies, posaconazole was found to be a valuable pharmaceutical agent for the treatment of life-threatening fungal infections. This review will examine the development history of posaconazole and highlight the most recent advances.

Posaconazole Tables 2.pdf (89 kB)
Table 1 and Table 2

Posaconazole Text Boxes.pdf (97 kB)
Posaconazole Text Box

Posaconazole Figures 2.pdf (403 kB)
Posaconazole Figures

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.